All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
One potential approach to achieving a functional HIV cure is to first reduce the size of the HIV reservoir and then engineer an immune response that can effectively control the shrunken reservoir in the absence of antiretroviral therapy. MicAbodies, comprised of full-length broadly neutralizing HIV antibodies coupled to a mutated ligand, selectively engage a mutant receptor that has been engineered as a chimeric antigen receptor (CAR) and expressed on CD8 T cells (convertibleCAR-T cells). The HIV-specific MicAbodies and the convertibleCAR-T cells can detect and eliminate HIV infected cells. The modularity of the convertibleCAR-T cell system allows multiplexing with several anti-HIV antibodies and yields greater breadth and control, thus making this platform a promising tool for attacking the latent HIV reservoir.
Creative Biolabs invited Dr. Eytan Herzig, a Staff Research Scientist in the Gladstone Center for HIV Cure Research, to share his profound insights on the principles and opportunities of innovative convertibleCAR-T platform in HIV cure.
During this webinar, the following topics were discussed:
Webinar Recording
Speaker Bio
Dr. Eytan Herzig is a Staff Research Scientist in the Gladstone Center for HIV Cure Research, where he leads the use of new technologies to fight HIV. After completing his Ph.D. education at the Tel Aviv University, he worked as a postdoctoral fellow at Tel Aviv University and at Gladstone.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION